JNJ-74856665
Phase 1Small molecule
Johnson & JohnsonJNJ-74856665 is one of 69 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
364 competitors in Myelodysplastic Syndrome
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Venclexta
AbbViePhase 3
Fludara
SanofiPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Idamycin
PfizerPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cellcept
RochePhase 3
Aranesp
AmgenPhase 3
Novantrone
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-74856665. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company